Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Reid

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Diabetes/Metabolism Research and Reviews|September 27, 2014
Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differencesCharles Shaefer, Timothy Reid, Andres DiGenio, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 16, 2018
Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support ProgramJennifer D Goldman, Jasvinder Gill, Tony Horn, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mLGeorge Dailey, Timothy Reid, John White, et al.
Journal of Managed Care & Specialty Pharmacy|March 30, 2022
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulinEugene E Wright, Daniel C Malone, Jennifer M Trujillo, et al.
European Endocrinology|June 7, 2018
A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 DiabetesJ Hans DeVries, Luigi Meneghini, Anthony H Barnett, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Diabetes/Metabolism Research and Reviews|September 27, 2014
Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differencesCharles Shaefer, Timothy Reid, Andres DiGenio, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 16, 2018
Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support ProgramJennifer D Goldman, Jasvinder Gill, Tony Horn, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mLGeorge Dailey, Timothy Reid, John White, et al.
Journal of Managed Care & Specialty Pharmacy|March 30, 2022
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulinEugene E Wright, Daniel C Malone, Jennifer M Trujillo, et al.
European Endocrinology|June 7, 2018
A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 DiabetesJ Hans DeVries, Luigi Meneghini, Anthony H Barnett, et al.
Pageof 2